Dianthus Therapeutics rises after William Blair starts coverage with 'outperform'

Dianthus Therapeutics

02/07/2025 16:08

** Clinical-stage biotechnology company Dianthus Therapeutics DNTH.O shares up ~4.6% to $18.78

** William Blair initiates coverage of DNTH with an "outperform" rating

** Brokerage says DNTH's management team carries significant experience, and collectively the team is well suited to execute clinical development and commercialization in the highly competitive autoimmune neuromuscular disorder market

** William Blair adds that CEO Marino Garcia's expertise will position Dianthus well as it transitions from a mid-stage clinical development company into a late-stage commercial entity over the next few years

** All of 12 brokerages rate the stock "buy" or higher; their median PT is $50 - LSEG data

** Including session's moves, stock down ~14.5% YTD

(Reporting by Prakhar Srivastava in Bengaluru)

((Prakhar.srivastava2@thomsonreuters.com))